Reil T D, Sarkar R, Kashyap V S, Sarkar M, Gelabert H A
UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California, 90095, USA.
J Surg Res. 1999 Jul;85(1):109-14. doi: 10.1006/jsre.1999.5665.
Experimental studies in vivo have demonstrated that dexamethasone inhibits neointimal hyperplasia following arterial injury. The mechanisms of this inhibition have not been clearly defined. Our objective was to test the hypothesis that dexamethasone directly suppresses smooth muscle cell (SMC) proliferation by inhibiting cell cycle progression and the expression of key cell cycle-dependent genes.
Cultured rat aortic SMC were treated with incremental concentrations of dexamethasone and cell number was determined after 72 h. To determine if dexamethasone inhibited cell cycle progression, cells were synchronized, then restimulated to enter the cell cycle, and treated with or without dexamethasone. DNA synthesis was determined 24 h after restimulation by measuring [3H]thymidine incorporation. To define the point of action of dexamethasone in the cell cycle, synchronized SMC were treated with dexamethasone (10(-7) M) at various time points after entry into the cell cycle. Flow cytometry and Northern blots were performed to examine cell cycle progression and the expression of smooth muscle cell cycle-dependent genes c-fos, c-myc, and thymidine kinase (TK).
Dexamethasone treatment induced a concentration-dependent inhibition of SMC proliferation and DNA synthesis. The cell cycle progression of synchronized SMC from G1 into S phase was inhibited by dexamethasone, even when added as late as 16 h after restimulation. The expression of TK was suppressed by dexamethasone, while c-fos and c-myc were not affected.
Dexamethasone inhibits the proliferation of SMC in a concentration-dependent fashion. This inhibition is associated with a block in cell cycle progression late in G1 phase of the cell cycle. Consistent with this finding, dexamethasone does not alter the expression of the early cell cycle-dependent genes c-fos and c-myc, but significantly inhibits the expression of TK, a marker of late G1 phase.
体内实验研究表明,地塞米松可抑制动脉损伤后的新生内膜增生。这种抑制作用的机制尚未明确。我们的目的是验证地塞米松通过抑制细胞周期进程和关键细胞周期依赖性基因的表达来直接抑制平滑肌细胞(SMC)增殖这一假说。
用递增浓度的地塞米松处理培养的大鼠主动脉平滑肌细胞,72小时后测定细胞数量。为确定地塞米松是否抑制细胞周期进程,使细胞同步化,然后重新刺激其进入细胞周期,并用地塞米松处理或不处理。重新刺激24小时后,通过测量[3H]胸腺嘧啶核苷掺入量来测定DNA合成。为确定地塞米松在细胞周期中的作用点,在进入细胞周期后的不同时间点,用地塞米松(10(-7)M)处理同步化的平滑肌细胞。进行流式细胞术和Northern印迹分析,以检测细胞周期进程以及平滑肌细胞周期依赖性基因c-fos、c-myc和胸苷激酶(TK)的表达。
地塞米松处理诱导了平滑肌细胞增殖和DNA合成的浓度依赖性抑制。即使在重新刺激后16小时才添加地塞米松,它也能抑制同步化的平滑肌细胞从G1期进入S期的细胞周期进程。地塞米松抑制了TK的表达,而c-fos和c-myc不受影响。
地塞米松以浓度依赖性方式抑制平滑肌细胞增殖。这种抑制与细胞周期G1期后期的细胞周期进程阻滞有关。与这一发现一致,地塞米松不改变早期细胞周期依赖性基因c-fos和c-myc的表达,但显著抑制G1期后期标志物TK的表达。